TRANSGENIC APPROACH TO SUPERIOR IMMUNODEFICIENT MICE

Information

  • Research Project
  • 3489277
  • ApplicationId
    3489277
  • Core Project Number
    R43AI030289
  • Full Project Number
    1R43AI030289-01A1
  • Serial Number
    30289
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/1991 - 33 years ago
  • Project End Date
    10/31/1991 - 33 years ago
  • Program Officer Name
  • Budget Start Date
    5/1/1991 - 33 years ago
  • Budget End Date
    10/31/1991 - 33 years ago
  • Fiscal Year
    1991
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    4/30/1991 - 33 years ago

TRANSGENIC APPROACH TO SUPERIOR IMMUNODEFICIENT MICE

DESCRIPTION: (Adapted from the applicant's abstract) The study of the immune system has been greatly enhanced by the discovery of naturally occurring immunodeficient mouse strains. Distinct T and B cell deficient mutants (e.g., SCID, nude, beige, and x-linked) have been widely used in studying immune cell differentiation and as animal models for human disease (e.g., leukemia, solid tumors, and HIV infection). The goal of Phase I study is to generate transgenic immunodeficient mice (TIM) as improved hosts for experimental transplantation of human tissues. The major objective is to combine both T and NK cell deficiencies. This will eliminate not only B cell differentiation (due to lack of T(helper) function) but also the major cytotoxic killer cell functions responsible for rejecting foreign tissues. The strategy is based upon evidence that both T and NK cells share a common protein critical to their functional differentiation. The gene for this protein will be inactivated by insertional mutagenesis in embryonic stem (ES) cells, and its promoter will be used to direct tissue specific expression of diptheria toxin and thus cell ablation of T and NK cells. In Phase II study, a series of animal models will be developed based upon the long term engraftment of human tissues.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    GENPHARM INTERNATIONAL, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN JOSE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    95131
  • Organization District
    UNITED STATES